Literature DB >> 19592130

The CD300 molecules regulate monocyte and dendritic cell functions.

Georgina J Clark1, Xinsheng Ju, Maryam Azlan, Courtney Tate, Yitian Ding, Derek N J Hart.   

Abstract

The CD300 glycoproteins are a family of related leucocyte surface molecules that modulate a diverse array of cell processes via their paired triggering and inhibitory receptor functions. All family members have a single Ig-V like domain and they share a common evolutionary pathway. At least one member of the family has undergone significant positive selection (ranked second in the top 50) indicating a need to maintain some crucial function. Here we have reviewed the CD300 family members, and their expression on cells of the monocyte and dendritic cell lineages. The consequences of CD300 molecule expression by these leucocyte lineages are only now beginning to be understood. The ability to fine tune monocyte and dendritic cell function and immune responses highlights several potential options to exploit these molecules as therapeutic targets in chronic inflammatory diseases, allergy and other disease states.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592130     DOI: 10.1016/j.imbio.2009.06.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  16 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

Authors:  Agueda Martínez-Barriocanal; Emma Comas-Casellas; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 3.  The Dual Tropism of Noroviruses.

Authors:  Christiane E Wobus
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 4.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

5.  CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Authors:  Rodolfo Silva; Susan Moir; Lela Kardava; Karen Debell; Venkateswara R Simhadri; Sara Ferrando-Martínez; Manuel Leal; José Peña; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

6.  Cloning and characterization of CD300d, a novel member of the human CD300 family of immune receptors.

Authors:  Emma Comas-Casellas; Águeda Martínez-Barriocanal; Francesc Miró; Aroa Ejarque-Ortiz; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

7.  All-trans-retinoic acid and Erk1/2 signaling synergistically regulate the expression of CD300B in human monocytic cells.

Authors:  Yong Wu; Qiuyan Chen; Tongkun Pai; A Catharine Ross
Journal:  Cell Immunol       Date:  2011-03-29       Impact factor: 4.868

8.  The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells.

Authors:  Dikla Lankry; Tihana Lenac Rovis; Stipan Jonjic; Ofer Mandelboim
Journal:  Eur J Immunol       Date:  2013-06-21       Impact factor: 5.532

9.  Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors:  Edward Abadir; Pablo A Silveira; Robin E Gasiorowski; Murari Ramesh; Adelina Romano; Ahmed H Mekkawy; Tsun-Ho Lo; Karieshma Kabani; Sarah Sutherland; Geoffrey A Pietersz; P Joy Ho; Christian E Bryant; Stephen R Larsen; Georgina J Clark
Journal:  Blood Adv       Date:  2020-04-14

10.  Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin.

Authors:  Sriram Narayanan; Rodolfo Silva; Giovanna Peruzzi; Yelina Alvarez; Venkateswara R Simhadri; Karen Debell; John E Coligan; Francisco Borrego
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.